PLx Pharma Inc
F:1D5A
PLx Pharma Inc
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
